Interview with BriaCell Therapeutics Corp.

New BriaCell interview with Dr. Bill Willams, and Dr. Giuseppe Del Priore Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO and Giuseppe Del Priore, MD, MPH, the Company’s Chief Medical Officer (CMO)of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the Company goals moving forward relating to its current and upcoming clinical trials including the ongoing Phase I/IIa combination study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s checkpoint inhibitors, retifanlimab and epacadostat in advanced breast cancer.

In February 2022, the Company announced the appointment of Giuseppe Del Priore, MD, MPH, as the Company’s Chief Medical Officer (CMO).
Dr. Del Priore is a seasoned healthcare executive with over 25 years of experience in research, drug development, and clinical trials management. Dr. Del Priore’s prior work experience includes serving as a biotech Chief Medical Officer, a National Director at the Cancer Treatment Centers of America (CTCA), plus faculty at Indiana University School of Medicine, Weill Cornell Medicine, and New York University School of Medicine.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at

Link to full disclosure about compensation paid to by companies featured on our website or in our e-mail communications.